Kyowa Kirin’s North America Expansion Progresses With Crysvita Commercial Takeover
Executive Summary
The Japanese pharma has taken over commercialization of the rare disease drug from Ultragenyx under a planned transition and as part of a broader growth strategy in North America.
You may also be interested in...
Kyowa Kirin links with Ultragenyx for first-in-class XLH therapy
Kyowa Hakko Kirin is tapping the specialist expertise of the private US venture Ultragenyx Pharmaceutical to speed up the development and commercialization of potentially the first specific therapy for the rare metabolic bone disorder X-linked hyperphosphatemia (XLH).
Jardiance Improves Double-Digit Growth Potential With US Approval In CKD
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.
Administrative Burden, Class-Wide Impacts Are Among IRA Pitfalls
As Medicare drug price negotiations creep closer to reality, industry leaders are turning attention to the challenges of implementation and commercial concerns.